-
Thematic Analysis
Transformational Power of Genomics in Pharma: Strategic Intelligence
Accelerating technologies within the genomics landscape: Several advancements in the pharmaceutical industry have enabled the field of genomics to expand, with researchers innovating new means of therapy for patients with a wide variety of diseases, subsequently enabling in-depth insights to be generated within the genomics landscape. Genomics therapies are paving the way for novel treatments that address the root cause of diseases, allowing additional resources to be allocated for efficient precision and personalized medicine therapies for the treatment of rare...
-
Sector Analysis
Bronchiectasis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2033
This report covers the 8MM (US, France, Germany, Italy, Spain, UK, Japan, China) and provides an Excel-based forecast model for the bronchiectasis market through 2033. Report deliverables include a PowerPoint report and an Excel-based forecast model. Bronchiectasis, which has been given diagnostic code of J47.9 from the International Classification of Diseases, Tenth Edition (ICD-10), is defined by damage to the bronchi, causing abnormal dilation and scarring. The airways become inflamed with thick mucus that is difficult to clear, which build-up...
-
Sector Analysis
Current Trends in Targeted Therapies in Non-Small Cell Lung Cancer (NSCLC) – Market Drivers and Challenges
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for approximately 85% of all lung cancer cases There are currently ten actionable genomic alterations (AGAs) that are addressed by targeted therapy agents across multiple lines of therapy. Patients who did not undergo genetic testing or tested negative for AGAs, receive immunotherapy agents depending on their PD-L1 status. Chemotherapy works as salvage therapy for late-line recurrent/relapsed patients. - Targeted therapy in NSCLC is a highly competitive...
-
Thematic Analysis
Biosimilars through Physician's Lens - Strategic Intelligence
Since their introduction within the past few decades, biosimilars outrivaled biologics in reducing treatment costs and improving access to therapies for chronic conditions such as cancer, rheumatoid arthritis (RA), and diabetes. Nevertheless, while biosimilars are increasingly recognized for their clinical and economic benefits, their uptake has been slower than anticipated in some markets. The physician’s role in shaping the future of biosimilar use is undeniable, given their influence on prescribing practices and patient trust. In this report, GlobalData examines biosimilar...
-
Sector Analysis
B-Cell Non-Hodgkin's Lymphoma Epidemiology Analysis and Forecast to 2033
Non-Hodgkin’s lymphoma (NHL) represents a group of cancers that develop in the lymphatic system. Individuals with NHL experience uncontrolled malignant white blood cells, rendering the immune system incapable of effectively fighting off infections. Among all malignant lymphomas, the 90% are composed of NHL, making it among the most prevalent hematological adult cancers (Ekströ Smedby et al., 2008). NHL is segmented by its histology into B-cell, T-cell, and natural killer lymphocyte lymphoma, with B-cell lymphoma constituting 80─85% of the three subtypes....
-
Sector Analysis
Phenylketonuria Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
This reports provides a data-driven overview of the current and future competitive landscape in Phenylketonuria Therapeutics. - GlobalData epidemiologists estimate that there were 498,757 diagnosed prevalent cases of Phenylketonuria in 2024, which is expected to increase slightly to 557,730 diagnosed prevalent cases by 2029. - PKU is managed through a combination of supportive care, chemotherapy, and targeted therapies. - The PKU pipeline holds 262 molecules, with two assets in the pre-registration stage, 16 assets in Phase III development, and 87...
-
Product Insights
Type 1 Diabetes (Juvenile Diabetes) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Type 1 Diabetes (Juvenile Diabetes) - Global Clinical Trials Review, 2025" provides an overview of Type 1 Diabetes (Juvenile Diabetes) Clinical trials scenario. This report provides top line data relating to the clinical trials on Type 1 Diabetes (Juvenile Diabetes). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
-
Product Insights
Acute Decompensated Heart Failure Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Acute Decompensated Heart Failure - Global Clinical Trials Review, 2025" provides an overview of Acute Decompensated Heart Failure Clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Decompensated Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
Erythrodermic Psoriasis Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Erythrodermic Psoriasis - Global Clinical Trials Review, 2025" provides an overview of Erythrodermic Psoriasis Clinical trials scenario. This report provides top line data relating to the clinical trials on Erythrodermic Psoriasis. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent...
-
Product Insights
Squamous Non-Small Cell Lung Cancer Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2025 Update
GlobalData's clinical trial report, “Squamous Non-Small Cell Lung Cancer - Global Clinical Trials Review, 2025" provides an overview of Squamous Non-Small Cell Lung Cancer Clinical trials scenario. This report provides top line data relating to the clinical trials on Squamous Non-Small Cell Lung Cancer. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.